NasdaqGS:BNTXBiotechs
Assessing BioNTech (NasdaqGS:BNTX) Valuation After Analyst Moves And COVID Vaccine Trial Setback
Analyst reactions and trial setback keep focus on BioNTech (NasdaqGS:BNTX)
Recent analyst actions, a CEO transition, softer COVID guidance, and the halt of recruitment in a major US COVID-19 vaccine trial have kept investor attention squarely on BioNTech (NasdaqGS:BNTX).
See our latest analysis for BioNTech.
Recent price action reflects that tension, with a 6.42% 7 day share price return and a 1.97% move higher in the latest session coming after a 10.56% 1 month share price decline and a...